Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 650

1.

Prospective Validation of an mRNA-based Urine Test for Surveillance of Patients with Bladder Cancer.

Valenberg FJPV, Hiar AM, Wallace E, Bridge JA, Mayne DJ, Beqaj S, Sexton WJ, Lotan Y, Weizer AZ, Jansz GK, Stenzl A, Danella JF, Shepard B, Cline KJ, Williams MB, Montgomery S, David RD, Harris R, Klein EW, Bradford TJ, Wolk FN, Westenfelder KR, Trainer AF, Richardson TA, Egerdie RB, Goldfarb B, Zadra JA, Ge S, Zhao S, Simon IM, Campbell SA, Rhees B, Bates MP, Higuchi RG, Witjes JA.

Eur Urol. 2018 Dec 12. pii: S0302-2838(18)30959-X. doi: 10.1016/j.eururo.2018.11.055. [Epub ahead of print]

PMID:
30553612
2.

Role of multiparametric magnetic resonance imaging for patients under active surveillance for prostate cancer: a systematic review with diagnostic meta-analysis.

Cantiello F, Russo GI, Kaufmann S, Cacciamani G, Crocerossa F, Ferro M, De Cobelli O, Artibani W, Cimino S, Morgia G, Damiano R, Nikolaou K, Kröger N, Stenzl A, Bedke J, Kruck S.

Prostate Cancer Prostatic Dis. 2018 Nov 28. doi: 10.1038/s41391-018-0113-2. [Epub ahead of print] Review.

PMID:
30487646
3.

Molecular predictors of response to PD-1/PD-L1 inhibition in urothelial cancer.

Stühler V, Maas JM, Bochem J, da Costa IA, Todenhöfer T, Stenzl A, Bedke J.

World J Urol. 2018 Oct 29. doi: 10.1007/s00345-018-2538-6. [Epub ahead of print]

PMID:
30374610
4.

mTOR and mTOR phosphorylation status in primary and metastatic renal cell carcinoma tissue: differential expression and clinical relevance.

Rausch S, Schollenberger D, Hennenlotter J, Stühler V, Kruck S, Stenzl A, Bedke J.

J Cancer Res Clin Oncol. 2019 Jan;145(1):153-163. doi: 10.1007/s00432-018-2775-5. Epub 2018 Oct 27.

PMID:
30368665
5.

[Mode of action, new targets and potential biomarkers in modern immunotherapy].

Bedke J, Stühler V, Todenhöfer T, Stenzl A.

Urologe A. 2018 Nov;57(11):1301-1308. doi: 10.1007/s00120-018-0787-z. Review. German.

PMID:
30350128
6.

Extended Versus Limited Lymph Node Dissection in Bladder Cancer Patients Undergoing Radical Cystectomy: Survival Results from a Prospective, Randomized Trial.

Gschwend JE, Heck MM, Lehmann J, Rübben H, Albers P, Wolff JM, Frohneberg D, de Geeter P, Heidenreich A, Kälble T, Stöckle M, Schnöller T, Stenzl A, Müller M, Truss M, Roth S, Liehr UB, Leißner J, Bregenzer T, Retz M.

Eur Urol. 2018 Oct 15. pii: S0302-2838(18)30737-1. doi: 10.1016/j.eururo.2018.09.047. [Epub ahead of print]

PMID:
30337060
7.

Trimodal therapy for muscle-invasive bladder cancer.

Mathes J, Rausch S, Todenhöfer T, Stenzl A.

Expert Rev Anticancer Ther. 2018 Dec;18(12):1219-1229. doi: 10.1080/14737140.2018.1535314. Epub 2018 Oct 17.

PMID:
30324833
8.

Can contrast-enhanced ultrasound and acoustic radiation force impulse imaging characterize CT-indeterminate renal masses? A prospective evaluation with histological confirmation.

Thaiss WM, Bedke J, Kruck S, Spira D, Stenzl A, Nikolaou K, Horger M, Kaufmann S.

World J Urol. 2018 Oct 15. doi: 10.1007/s00345-018-2520-3. [Epub ahead of print]

PMID:
30324296
9.

Can urinary biomarkers replace cystoscopy?

Maas M, Bedke J, Stenzl A, Todenhöfer T.

World J Urol. 2018 Oct 3. doi: 10.1007/s00345-018-2505-2. [Epub ahead of print]

PMID:
30283995
10.

DNA methylation of neural EGFL like 1 (NELL1) is associated with advanced disease and the metastatic state of renal cell cancer patients.

Peters I, Dubrowinskaja N, Hennenlotter J, Antonopoulos WI, Von Klot CAJ, Tezval H, Stenzl A, Kuczyk MA, Serth J.

Oncol Rep. 2018 Dec;40(6):3861-3868. doi: 10.3892/or.2018.6732. Epub 2018 Sep 24.

PMID:
30272321
11.

Selective Inhibition of the Lactate Transporter MCT4 Reduces Growth of Invasive Bladder Cancer.

Todenhöfer T, Seiler R, Stewart C, Moskalev I, Gao J, Ladhar S, Kamjabi A, Al Nakouzi N, Hayashi T, Choi S, Wang Y, Frees S, Daugaard M, Oo HZ, Fisel P, Schwab M, Schaeffeler E, Douglas J, Hennenlotter J, Bedke J, Gibb EA, Fazli L, Stenzl A, Black PC.

Mol Cancer Ther. 2018 Dec;17(12):2746-2755. doi: 10.1158/1535-7163.MCT-18-0107. Epub 2018 Sep 27.

PMID:
30262589
12.

Calgranulin A (S100A8) Immunostaining: A Future Candidate for Risk Assessment in Patients with Non-Muscle-Invasive Bladder Cancer (NMIBC).

Nicklas AP, Kramer MW, Serth J, Hennenlotter J, Hupe MC, Reimer DU, Stenzl A, Merseburger AS, Kuczyk MA, von Klot CJ.

Adv Ther. 2018 Nov;35(11):2054-2068. doi: 10.1007/s12325-018-0789-7. Epub 2018 Sep 19.

13.

Transketolase like 1 (TKTL1) expression alterations in prostate cancer tumorigenesis.

da Costa IA, Hennenlotter J, Stühler V, Kühs U, Scharpf M, Todenhöfer T, Stenzl A, Bedke J.

Urol Oncol. 2018 Oct;36(10):472.e21-472.e27. doi: 10.1016/j.urolonc.2018.06.010. Epub 2018 Aug 16.

PMID:
30119993
14.

Systemic Alterations of Wnt Inhibitors in Patients with Prostate Cancer and Bone Metastases.

Aufderklamm S, Hennenlotter J, Leidenberger P, Rausch S, Hohneder A, Kühs U, Maas M, Schwentner C, Bedke J, Stenzl A, Todenhöfer T.

Dis Markers. 2018 Jul 18;2018:1874598. doi: 10.1155/2018/1874598. eCollection 2018.

15.

Characterization of the breast cancer resistance protein (BCRP/ABCG2) in clear cell renal cell carcinoma.

Reustle A, Fisel P, Renner O, Büttner F, Winter S, Rausch S, Kruck S, Nies AT, Hennenlotter J, Scharpf M, Fend F, Stenzl A, Bedke J, Schwab M, Schaeffeler E.

Int J Cancer. 2018 Dec 15;143(12):3181-3193. doi: 10.1002/ijc.31741. Epub 2018 Sep 25.

PMID:
30070687
16.

Clinical utility of the S3-score for molecular prediction of outcome in non-metastatic and metastatic clear cell renal cell carcinoma.

Büttner F, Winter S, Rausch S, Hennenlotter J, Kruck S, Stenzl A, Scharpf M, Fend F, Agaimy A, Hartmann A, Bedke J, Schwab M, Schaeffeler E.

BMC Med. 2018 Jul 5;16(1):108. doi: 10.1186/s12916-018-1088-5.

17.

Suture causing urethral meatus stricture: A novel animal model of partial bladder outlet obstruction.

Chen L, Yang Y, Yang J, He P, Amend B, Stenzl A, Hu J, Zhang Y, Wang Z.

Neurourol Urodyn. 2018 Sep;37(7):2088-2096. doi: 10.1002/nau.23427. Epub 2018 Jun 28.

PMID:
29953650
18.

Single-use versus reusable ureterorenoscopes for retrograde intrarenal surgery (RIRS): systematic comparative analysis of physical and optical properties in three different devices.

Deininger S, Haberstock L, Kruck S, Neumann E, da Costa IA, Todenhöfer T, Bedke J, Stenzl A, Rausch S.

World J Urol. 2018 Dec;36(12):2059-2063. doi: 10.1007/s00345-018-2365-9. Epub 2018 Jun 5.

PMID:
29869701
19.

Transurethral Resection of Bladder Tumors: Next-generation Virtual Reality Training for Surgeons.

Neumann E, Mayer J, Russo GI, Amend B, Rausch S, Deininger S, Harland N, da Costa IA, Hennenlotter J, Stenzl A, Kruck S, Bedke J.

Eur Urol Focus. 2018 May 22. pii: S2405-4569(18)30101-9. doi: 10.1016/j.euf.2018.04.011. [Epub ahead of print]

PMID:
29802051
20.

[Current and established diagnostic modalities for bladder cancer].

Zaak D, Ohlmann C, Stenzl A.

Urologe A. 2018 May 9. doi: 10.1007/s00120-018-0650-2. [Epub ahead of print] Review. German.

PMID:
29744554

Supplemental Content

Loading ...
Support Center